Lewis, Amanda J. https://orcid.org/0000-0001-7257-5848
van den Heuvel, Lukas https://orcid.org/0000-0001-9168-8450
Di Fabrizio, Marta
Bandelier, Kaliya
Proniakova, Daria
Burger, Domenic
Shafiei, Notash https://orcid.org/0009-0005-4567-9795
Ekundayo, Kazadi https://orcid.org/0009-0003-1824-0037
Offringa, Selene https://orcid.org/0009-0009-1148-2707
Huisman, Evelien
Bol, John GJM
van de Berg, Wilma DJ https://orcid.org/0000-0002-6175-5357
Stahlberg, Henning https://orcid.org/0000-0002-1185-4592
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_188548)
EC | Horizon 2020 Framework Programme (No. 101118656)
Stiftung Synapsis - Alzheimer Forschung Schweiz AFS (2019-CDA01)
Parkinson Schweiz; Dutch Parkinson Association
Article History
Received: 27 February 2026
Accepted: 29 May 2026
First Online: 8 June 2026
Competing interests
: DB is an employee of F.Hoffman-La Roche Ltd.; the work reported here was conducted prior to the commencement of this employment. WVdB is a recipient of ‘ProPARK’, a public–private partnership receiving funding from ZonMW (40-46000-98-101), Hersenstichting, Parkinson Vereniging, PHARMO Institute NV, Stichting Woelse Waard, Stichting Alkemade-Keuls fonds, CHDR, ABBVIE, Hoffman-La Roche and OccamzRazor. WVdB received funding for a public–private partnership ‘CONCERT’ and ‘ADAPT-PD’ from Health~Holland, Topsector Life Sciences & Health in collaboration with Roche and Genentech. WVdB performed contract research for Roche Tissue Diagnostics, Discoveric Bio Alpha, AC Immune and Gain Therapeutics. All funding has been paid to Amsterdam UMC. WVdB is a member of the scientific advisory board of Gain Therapeutics, Alzheimer Nederland and PACE Lundbeck Foundation Parkinson’s Disease Research Center. WVdB is the president of the Dutch association for Parkinson Scientists and a member of the board of the Parkinsonalliance Netherlands. The remaining authors declare no competing interests.